WallStSmart
LH

Laboratory Corporation of America Holdings

NYSE: LH · HEALTHCARE · DIAGNOSTICS & RESEARCH

$257.14
-0.94% today

Updated 2026-04-29

Market cap
$21.19B
P/E ratio
24.56
P/S ratio
1.52x
EPS (TTM)
$10.47
Dividend yield
1.11%
52W range
$237 – $292
Volume
0.6M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Laboratory Corporation of America Holdings (LH) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$257.14
Consensus
$308.30
+19.90%
2030 Target
$2,572.97
+900.61%
DCF
$314.31
+7.77% MoS
10 analysts:
5 Buy2 Hold0 Sell

Management guidance

No specific revenue targets or growth guidance provided by CEO Adam Schechter in available materials. Company has communicated strong demand for diagnostic products and specialty testing capabilities, but specific revenue projections for 2026-2030 are not disclosed in public guidance.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$4,297.40
$17.8B Rev × 20x P/S
Base case (2030)
$2,572.97
$17.8B Rev × 12x P/S
Bear case (2030)
$1,724.44
$17.8B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$12.2B$13.0B$14.0B$15.1B$15.8B$16.4B$17.1B$17.8B
Revenue growth—7.0%7.2%8.3%4.8%3.9%3.9%4.0%
EPS$14.30$14.57$16.44$18.42$19.86$21.24$22.68$24.21
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$2,189.76$2,299.25$2,381.36$2,463.48$2,572.97

Catalysts & risks

Growth catalysts
+ FDA-cleared Alzheimer's blood test launch expanding diagnostic TAM
+ Digital pathology platform expansion via PathAI collaboration nationwide
+ Illumina precision oncology testing partnership broadening access
+ Specialty testing and hospital partnerships offsetting volume challenges
+ Strategic acquisitions (NY pathology reference lab, medical device testing assets)
+ AI-driven pathology market growth and MRD testing expansion for cancer recurrence
Key risks
- Medicare reimbursement cuts impacting clinical lab margins
- Stagnant historical revenue growth (5-year CAGR near 0%)
- Volume pressure in core diagnostic testing despite specialty gains
- Workforce reductions (83 jobs eliminated at Raritan facility)
- Competitive pressure from Quest Diagnostics and regional labs
- Macroeconomic sensitivity affecting patient volumes and healthcare spending

Methodology

Laboratory Corporation of America Holdings's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 10 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.